Source comparison
Thymosin Alpha-1 Cycle Length: Protocol Comparison
Acute Immune Challenge 4–6 weeks 1.6mg SC twice weekly None required Post-surgical infection risk, acute viral exposure, chemotherapy support Best for time-sensitive immune upregulation; sufficient for T-cell priming but not long-term memory consolidation Stan
This comparison does not assign a generated winner or score.
- Acute Immune Challenge
- 4–6 weeks
- 1.6mg SC twice weekly
- None required
- Post-surgical infection risk, acute viral exposure, chemotherapy support
- Best for time-sensitive immune upregulation; sufficient for T-cell priming but not long-term memory consolidation
- Standard Immune Modulation
- 8–12 weeks
- Optional 4-week terminal washout
- Vaccine response enhancement, seasonal immune support, general immunosenescence models
- Evidence-backed sweet spot. Maximal T-cell differentiation without receptor desensitization risk
- Chronic Disease Protocol
- 6–12 months
- Mandatory 4 weeks off every 12 weeks
- Hepatitis B/C, HIV, autoimmune conditions, cancer immunotherapy adjunct
- Required for sustained immune pressure; washout intervals are non-negotiable to maintain efficacy
- High-Frequency Acute
- 2–3 weeks
- 1.6mg SC daily or every other day
- Severe acute immune deficiency, critical care models
- Rarely used; daily dosing shows no advantage over twice-weekly in most immune markers